UK, EU nations rally behind Astra jab after South Africa halts roll-out

South Africa looks to J&J vaccine

AstraZeneca
French Health Minister Olivier Veran voiced support for the AstraZeneca vaccine, arguing it provided sufficient protection against "nearly all the variants" of the virus | Photo: Reuters
Agencies
2 min read Last Updated : Feb 09 2021 | 2:56 AM IST
British Prime Minister Boris Johnson said on Monday that he was confident that both the AstraZeneca and Pfizer Covid-19 vaccines helped prevent death and grave illness, and that medicine was slowly gaining the upper hand over the coronavirus.

"We think that both the vaccines that we're currently using are effective in, as I say, in stopping serious disease and death," Johnson told reporters.

"We also think in particular in the case of the Oxford AstraZeneca vaccine that there's good evidence that it is stopping transmission, as well, I think 67 per cent reduction in transmission."


Western governments rushed to offer support for the AstraZeneca vaccination after South Africa halted its roll-out when research showed it offered minimal protection against mild infection from a variant spreading there.

French Health Minister Olivier Veran voiced support for the AstraZeneca vaccine, arguing it provided sufficient protection against "nearly all the variants" of the virus.

German Health Minister Jens Spahn said current evidence suggests all three vaccines approved in Europe — which include AstraZeneca — provided effective protection against serious infections.

Meanwhile, Johnson & Johnson will speed up deliveries of its vaccine to South Africa, a senior government official said, after the country suspended plans to roll out AstraZeneca shots due to disappointing trial data. 


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusAstraZenecaJ&JCoronavirus VaccineUKEuropean UnionSouth Africa

Next Story